Clinical Trial Update: The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated the effects of long-acting aripiprazole on myelin integrity and cognitive function in schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Aripiprazole long-acting injectable (aripiprazole)

Snippet

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Conditions: Schizophrenia, Myelin Degeneration | Phase 4 | Status: COMPLETED